Scheme for administering N-hydroxy-4-{2-3-(N.N-dimethylaminomethyl)­benzofuran-2-ylcarbonylaminoethoxy}benzamide

摘要

#$%^&*AU2016202594A120160519.pdf#####NEW ADMINISTRATION REGIME FOR N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2YLCARBONYLAMINO]ETHOXY}BENZAMIDE ABSTRACT N-hydroxy-4-12-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide of formula (I): 0 0 N H(J _0 =0 HN OH or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with a surgery, chemotherapy, hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that chemotherapy is not FOLFOX. Medicaments are also disclosed.